Enterprise Value

44.97M

Cash

16.69M

Avg Qtr Burn

-5.184M

Short % of Float

0.60%

Insider Ownership

11.62%

Institutional Own.

56.56%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AVTX-803 (CERC-803) Details
Leukocyte Adhesion Deficiency Type II

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Update

AVTX-007 (CERC-007) Details
Adult Onset Still's Disease

Phase 1b

Update

Phase 1b

Update

AVTX-006 (CERC-006) Details
Lymphatic malformations

Failed

Discontinued

AVTX-801 (CERC-801) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued

AVTX-802 (CERC-802) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued